Abstract:The Wnt/β-catenin signaling pathway plays extensive roles in cancer initiation, proliferation, and development, and has been implicated in the regulation of stem cells in the intestinal crypt, widely accepted as responsible for colorectal cancer (CRC) origination. This pathway has been a target of interest for many years for chemotherapeutic development of CRC due to its implication in most cases. Previously, a series of naphthoquinone analogs have been identified to inhibit the Wnt/β-catenin. It was postulated that these compounds exhibit their inhibitory activity via binding to β-catenin at the β-catenin/TCF4 interaction interface. In this study, we aimed to further define the critical pharmacophore for these compounds and verify their mechanisms of action for their abilities to inhibit the Wnt/β-catenin signaling pathway. Interestingly, our data suggested two of the compounds, compounds 3 and 6, may potently inhibit the Wnt/β-catenin signaling pathway via inhibition of the TCF4/DNA interaction, a novel finding compared to previous studies on these compounds. Our computational studies suggested that the compounds bound within the DNA binding HMG-box domain of TCF4 to elicit their inhibitory action. These compounds inhibited Wnt signaling in a dose dependent manner, suppressed Wnt direct target genes and demonstrated unforeseen degradation of the TCF4 protein. Thus, this study revealed a potentially novel mechanism of action of the chloro-naphthoquinone as possibly a multi-targeting scaffold, which warrants further investigation in future drug discovery on the 'undruggable" TCF proteins and an aberrantly activated Wnt/β-catenin signaling pathway.

Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction.

Development of Structure-Based Pharmacophore to Target the Β-Catenin-tcf Protein–protein Interaction

Discovery of Novel 1-Phenylpiperidine Urea-Containing Derivatives Inhibiting β-Catenin/BCL9 Interaction and Exerting Antitumor Efficacy through the Activation of Antigen Presentation of cDC1 Cells

Molecular docking-aided identification of small molecule inhibitors targeting β-catenin-TCF4 interaction

Discovery Of An Orally Bioavailable Small-Molecule Inhibitor For The Beta-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction

Discovery of Selective Small-Molecule Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety.

C644‐0303, a small‐molecule inhibitor of the Wnt/β‐catenin pathway, suppresses colorectal cancer growth

Discovery of Novel Inhibitor for WNT/-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening

Discovery of 2-(isoxazol-5-yl)phenyl 3,4-dihydroxybenzoate as a potential inhibitor for the Wnt/β-catenin pathway

Targeting XBP1-mediated Β-Catenin Expression Associated with Bladder Cancer with Newly Synthetic Oridonin Analogues.

Identification and biological evaluation of fused tetrahydroisoquinoline derivatives as Wnt/β-catenin signaling inhibitors to suppress colorectal cancer

Discovery of 2-(3-(3-carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives As Novel Small-Molecule Inhibitors of the Β-Catenin/b-cell Lymphoma 9 Protein–Protein Interaction

Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.

Structure-Based Optimization of Small-Molecule Inhibitors for the Β-Catenin/b-cell Lymphoma 9 Protein-Protein Interaction.

Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners

Rational design of selective small-molecule inhibitors for β-catenin/B-cell lymphoma 9 protein-protein interactions.

Design, Synthesis and Biological Evaluation of Quercetin Derivatives As Novel Β-Catenin/b-cell Lymphoma 9 Protein−protein Interaction Inhibitors

Pharmacological Inhibition of Β-Catenin/bcl9 Interaction Overcomes Resistance to Immune Checkpoint Blockades by Modulating T Reg Cells

Exploration of naphthoquinone analogs in targeting the TCF-DNA interaction to inhibit the Wnt/β-catenin signaling pathway

Discovery of small molecule β-catenin suppressors that enhance immunotherapy

Direct Targeting of Β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling.